All vaccine from Mustamäe
Up to now, no medicine has been produced for any patient in Mustamäe lab; even so, the entire process has been rehearsed to the detail and tested so the medicine would meet all quality requirements. At the moment, the specialists are preparing the lysate of melanoma cells – to be ready by April when the first blood comes from Italy.
«It’s a festive feeling to be in a place like that, not even trying to play modesty,» smiles Mr Raik. He’s also proud that while the initial idea was to only have Estonians do a tiny part of the process, now, after a year, they have succeeded to have the entire vaccine production for themselves.
What’s more: in addition to three-year contract to produce the medicine, the Estonian firm has also secured from Danes the global sole right to produce the lysate from melanoma cells.
«No matter who and where will be producing the medicine later, we will be producing the lysate for it,» says Mr Raik.
«In this company, we detected great business potential and, therefore, we invested into it. To boost the economy, business has to be connected with science and research,» says Development Fund chief Pirko Konsa. The fund has invested €350,000 into Cellin Technologies.